Journal
FUTURE MEDICINAL CHEMISTRY
Volume 6, Issue 17, Pages 1967-1984Publisher
Newlands Press Ltd
DOI: 10.4155/fmc.14.116
Keywords
-
Categories
Funding
- Austrian Science Fund (FWF) [I519-B11]
- Johanna Mahlke geb. Obermann foundation
- Austrian Science Fund (FWF) [I519] Funding Source: Austrian Science Fund (FWF)
- Austrian Science Fund (FWF) [I 519] Funding Source: researchfish
Ask authors/readers for more resources
The discovery of miRNAs as important regulatory agents for gene expression has expanded the therapeutic opportunities for oligonucleotides. In contrast to siRNA, miRNA-targeted therapy is able to influence not only a single gene, but entire cellular pathways or processes. It is possible to supplement downregulated or non-functional miRNAs by synthetic oligonucleotides, as well as alleviating effects caused by overexpression of malignant miRNAs through artificial antagonists, either oligonucleotides or small molecules. Chemical oligonucleotide modifications together with an efficient delivery system seem to be mandatory for successful therapeutic application. While miRNA-based therapy benefits from the decades of research spent on other therapeutic oligonucleotides, there are some specific challenges associated with miRNA therapy, mainly caused by the short target sequence. The current status and recent progress of miRNA-targeted therapeutics is described and future challenges and potential applications in treatment of cancer and viral infections are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available